Harmony Biosciences Holdings, Inc. today announced its participation in the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco, CA.
| PLYMOUTH MEETING, Pa., Jan. 3, 2024 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. (“Harmony” or the “Company”) (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare neurological diseases, today announced its participation in the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco, CA. Jeffrey M. Dayno, M.D., President and Chief Executive Officer of Harmony, is scheduled to present at the conference on Wednesday, January 10, 2024, at 5:15 p.m. PT/8:15 p.m. ET.
A live webcast of the presentation will be available on the investor page of Harmony’s website at https://ir.harmonybiosciences.com/. About Harmony Biosciences At Harmony Biosciences, we specialize in developing and delivering treatments for rare neurological diseases that others often overlook. We believe that where empathy and innovation meet, a better life can begin for people living with neurological diseases. Established by Paragon Biosciences, LLC, in 2017 and headquartered in Plymouth Meeting, PA, our team of experts from a wide variety of disciplines and experiences is driven by our shared conviction that innovative science translates into therapeutic possibilities for our patients, who are at the heart of everything we do. For more information, please visit www.harmonybiosciences.com. Harmony Biosciences Investor Contact: Harmony Biosciences Media Contact:
SOURCE Harmony Biosciences | ||
Company Codes: NASDAQ-NMS:HRMY |
View original content to download multimedia:
